Susmed (4263) · RiskRestated
Intensifying competition in the therapeutic app industry
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2023.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Overseas entry into and intensifying competition in the therapeutic app marketA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「The domestic competitive environment is becoming more challenging, as Japanese pharmaceutical companies have begun introducing therapeutic apps from overseas into Japan and launching clinical trials.」
The Company continues to describe the challenging competitive environment resulting from the introduction of therapeutic apps from overseas into Japan and other factors. - FY2022First statedAnnual report
「The domestic competitive environment is becoming more challenging, as Japanese pharmaceutical companies have begun introducing therapeutic apps from overseas into Japan and launching clinical trials.」
The Company indicates that competition in therapeutic app research and development, clinical trials, and sales may intensify as overseas companies and apps are introduced into Japan.